Millipore Sigma Vibrant Logo

345832 Galectin-3C, Human, Recombinant, E. coli

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
View Products on Sigmaaldrich.com
345832
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
345832-100UG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 100 μg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewRecombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
      Catalogue Number345832
      Brand Family Calbiochem®
      References
      ReferencesHoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
      John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
      Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
      Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
      Inohara, H. 1999. Cancer 85, 2475.
      Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
      Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
      Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
      Castronovo, V., et al. 1996. J. Pathol. 179, 43.
      Liu, F.T., et al. 1996. Biochemistry 35 6073.
      Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
      Massa, S.M., et al. 1993. Biochemistry 32, 260.
      Oda, Y., et al. 1991. Gene 99, 279.
      Product Information
      FormLyophilized
      FormulationLyophilized from deionized water, 2µg lactose/µg lectin.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      Physicochemical Information
      ContaminantsEndotoxin: ≤ 1 EU/µg protein
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      345832-100UG 04055977214352

      Documentation

      Galectin-3C, Human, Recombinant, E. coli FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Galectin-3C, Human, Recombinant, E. coli Certificats d'analyse

      TitreNuméro de lot
      345832

      Références bibliographiques

      Aperçu de la référence bibliographique
      Hoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
      John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
      Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
      Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
      Inohara, H. 1999. Cancer 85, 2475.
      Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
      Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
      Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
      Castronovo, V., et al. 1996. J. Pathol. 179, 43.
      Liu, F.T., et al. 1996. Biochemistry 35 6073.
      Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
      Massa, S.M., et al. 1993. Biochemistry 32, 260.
      Oda, Y., et al. 1991. Gene 99, 279.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision30-June-2008 RFH
      DescriptionRecombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histiolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
      FormLyophilized
      FormulationLyophilized from deionized water, 2µg lactose/µg lectin.
      Purity≥95% by SDS-PAGE
      ContaminantsEndotoxin: ≤ 1 EU/µg protein
      SolubilitySterile PBS (1 mg/ml)
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
      Toxicity Standard Handling
      ReferencesHoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
      John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
      Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
      Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
      Inohara, H. 1999. Cancer 85, 2475.
      Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
      Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
      Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
      Castronovo, V., et al. 1996. J. Pathol. 179, 43.
      Liu, F.T., et al. 1996. Biochemistry 35 6073.
      Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
      Massa, S.M., et al. 1993. Biochemistry 32, 260.
      Oda, Y., et al. 1991. Gene 99, 279.